first
pandem
centuri
unexpectedli
caus
novel
swineorigin
viru
pandem
viru
mexico
first
countri
affect
earli
march
report
mild
respiratori
infect
well
sever
pneumonia
case
consider
mortal
sever
countri
subsequ
affect
report
variabl
mortal
smoke
pregnanc
obes
import
risk
factor
sever
diseas
august
yearold
girl
without
histori
known
risk
factor
succumb
infect
pune
western
india
repres
first
fatal
countri
april
india
report
death
pandem
http
pune
contribut
case
http
wwwmahaarogyagovinmarchapril
initi
phase
pandem
design
ward
govern
hospit
admit
everi
mild
case
treat
oseltamivir
discharg
recoveri
special
intens
care
unit
treat
critic
ill
patient
present
studi
undertaken
earli
phase
pandem
understand
basi
differenti
diseas
presentationoutcom
investig
mild
case
critic
ill
patient
august
septemb
report
provid
compar
data
viral
load
cytokin
geneprofil
tolllikereceptor
tlr
level
antibodi
titr
antibodi
isotyp
ethic
clearanc
studi
obtain
institut
human
ethic
committe
part
pandem
influenza
investig
written
consent
obtain
particip
involv
studi
minor
critic
ill
patient
obtain
parentguardian
patient
confirm
infect
posit
real
time
pcr
test
http
studi
includ
patient
admit
intens
care
unit
requir
mechan
ventil
support
suffer
mild
respiratori
symptom
mild
case
ambulatori
patient
admit
design
hospit
initi
phase
pandem
studi
perform
patient
suggest
influenzalik
ill
admit
design
ward
corpor
hospit
throat
swab
collect
sent
nation
institut
virolog
diagnosi
osletamivir
treatment
initi
immedi
confirm
diagnosi
patient
discharg
complet
treatment
contrari
major
sever
patient
admit
develop
seriou
respiratori
consequ
protocol
follow
diagnosi
antivir
treatment
singl
blood
sampl
collect
mild
case
day
develop
respiratori
symptom
control
blood
sampl
appar
healthi
individu
collect
sequenti
bloodlung
aspir
sampl
standard
tracheal
aspir
collect
critic
ill
patient
first
sampl
collect
within
day
patient
one
collect
pregnant
woman
day
appear
symptom
tabl
blood
lung
aspir
transport
lab
within
half
hour
collect
lung
aspir
obtain
sever
case
immedi
aliquot
frozen
aliquot
mix
proport
rnalat
store
gene
analysi
hundr
microlitr
blood
sampl
everi
patient
process
immedi
tlr
stain
describ
parallel
blood
sampl
immedi
process
isol
peripher
blood
mononuclear
cell
pbmc
densiti
gradient
centrifug
use
ficollhypaqu
sigma
plasma
layer
remov
store
aliquot
cell
pellet
store
rnalat
solut
ambion
highli
sensit
specif
elisa
carri
coat
well
purifi
recombin
ha
protein
express
baculoviru
system
viru
sera
dilut
antihumanigghrp
conjug
detector
antibodi
isotyp
done
describ
earlier
antihuman
antibodi
tlr
ebiosci
usa
tlr
tlr
imgenex
usa
use
stain
surfac
stain
tlr
whole
blood
lyse
bd
fac
lysi
solut
bd
bioscienc
usa
wash
fix
process
stain
antihuman
tlr
fitc
conjug
tlr
pe
conjug
antibodi
respect
intracellular
stain
whole
blood
fulli
lyse
bd
fac
lyse
solut
becton
dickinson
wash
twice
permwash
buffer
bd
bioscienc
process
stain
follow
antihuman
antibodi
pe
tlr
fitc
tlr
fitc
petlr
respect
stain
cell
resuspend
paraformaldehyd
analys
facscalibur
flow
cytomet
becton
dickinson
basi
forward
side
scatter
plot
lymphocyt
monocyt
gate
data
analysi
done
use
bd
facsdivasoftwaretlr
level
express
median
fluoresc
intens
mfi
concentr
plasmalung
aspir
determin
seventeen
cytokineschemokin
mif
trail
bioplex
protein
array
system
biorad
hercul
ca
usa
use
milliplex
map
kit
millipor
per
manufactur
instruct
frozen
lung
aspir
thaw
centrifug
pellet
cell
pellet
use
isol
rna
total
rna
extract
pbmc
lung
aspir
cell
use
ribopur
kit
ambion
per
manufactur
instruct
rna
elut
elut
buffer
quantit
use
nanodrop
process
qualiti
check
agil
bioanalyz
agil
usa
equal
quantiti
rna
ng
rin
valu
process
cdna
synthesi
use
high
capac
cdna
revers
transcript
kit
appli
biosystem
uk
cdna
test
real
time
pcr
assay
use
taqman
primer
probe
rrna
appli
biosystem
uk
ensur
effici
cdna
synthesi
cdna
mix
equal
volum
taqman
pcr
master
mix
onestep
rtpcr
kit
appli
biosystem
ng
rna
equival
cdna
load
per
port
taqman
low
densiti
array
card
tlda
human
immun
panel
appli
biosystem
uk
run
fast
realtim
pcr
system
appli
biosystem
uk
rel
gene
express
valu
obtain
employ
compar
ct
method
use
appli
biosystem
rel
quantif
rq
manag
softwar
cdna
six
healthi
individu
process
similarli
consid
calibr
rna
use
endogen
control
rel
quantit
valu
studi
group
use
calcul
mean
rq
valu
cluster
analysi
rel
quantit
valu
transform
hierarch
cluster
analysi
softwar
cluster
viral
rna
extract
plasmalung
aspir
use
qiaamp
viral
rna
mini
kit
qiagen
germani
per
manufactur
instruct
viral
rna
quantit
cdc
primer
probe
use
target
ha
gene
indian
isol
clone
obtain
vitro
transcript
serial
dilut
rna
use
gener
refer
curv
linear
relationship
obtain
start
copiesreact
detect
limit
copi
level
cytokin
chemokin
analyz
log
transform
valu
pgml
use
case
undetect
concentr
cytokin
chemokin
test
sampl
mannwhitney
u
fisher
exact
test
use
group
comparison
numer
categor
data
respect
analys
p
valu
less
deriv
two
tail
test
consid
signific
statist
analys
perform
window
softwar
spss
inc
plasma
sampl
patient
categori
neg
influenza
viru
rna
sequenti
lung
aspir
sampl
patient
sampl
demonstr
gradualcontinu
lower
viral
load
singl
lung
aspir
patient
rapid
death
two
neg
viral
rna
one
exhibit
copiesml
figur
serum
sampl
avail
critic
ill
patient
exhibit
hi
titr
admiss
geometr
mean
titr
gmt
antibodi
elisa
significantli
lower
mild
infect
ci
valu
critic
ill
patient
ci
valu
p
last
blood
sampl
collect
day
later
critic
ill
patient
show
fold
rise
antibodi
titr
exclus
isotyp
categori
figur
show
repres
fac
plot
tlr
analysi
express
significantli
higher
mild
case
control
p
respect
differ
p
figur
comparison
diseas
categori
reveal
signific
decreas
tlr
p
rise
level
p
respect
critic
ill
patient
level
remain
unchang
p
comparison
among
healthi
control
diseas
categori
show
differ
level
significantli
lower
mild
case
higher
critic
ill
patient
tabl
molecul
show
significantli
higher
level
patient
categori
overal
pattern
reflect
influenza
infect
diseas
sever
correl
signific
increas
level
critic
ill
patient
larg
number
gene
significantli
downregul
critic
ill
patient
mild
case
tnf
faslg
hla
dra
ico
ace
gnli
gzmb
ikbkb
lta
tabl
repres
statu
cytokin
chemokin
protein
gene
level
respect
lung
aspiratescel
lung
aspir
critic
ill
patient
absenc
similar
sampl
mild
caseshealthi
control
ethic
reason
comparison
possibl
comparison
plasma
lung
aspir
critic
ill
patient
identifi
higher
level
lung
aspir
signific
differ
note
molecul
none
plasma
marker
sever
exhibit
higher
level
lung
aspir
follow
pattern
emerg
gene
profil
comparison
pbmc
lung
cell
critic
ill
patient
express
pattern
gene
also
analyz
hierarch
cluster
result
graphic
repres
assign
specif
color
cell
basi
express
level
gene
show
chang
express
level
compar
control
shown
black
upregul
gene
shown
red
increas
intens
proport
express
level
differ
intens
green
indic
level
downregul
figur
show
cluster
imag
sampl
mild
critic
ill
case
taken
admiss
season
flu
sampl
show
distinct
gene
express
pattern
form
separ
cluster
cluster
sampl
three
lung
sampl
critic
ill
patient
also
form
separ
cluster
proinflammatori
gene
upregul
cluster
remain
sampl
form
mix
cluster
cluster
includ
mild
critic
ill
patient
overal
distinct
cluster
pattern
patient
observ
sever
mild
case
respect
gene
cluster
cluster
b
contain
gene
associ
inflamm
comparison
gene
lung
pbmc
patient
critic
ill
patient
group
yield
similar
result
comparison
lung
cytokin
chemokin
protein
gene
level
show
compar
elev
level
tnf
elev
gene
level
ifng
basal
level
gene
protein
level
variabl
number
sequenti
blood
sampl
avail
critic
ill
patient
comparison
tlr
show
distinguish
pattern
data
shown
evalu
gene
express
separ
cluster
analysi
carri
sequenti
pbmc
sampl
critic
ill
patient
figur
sampl
form
two
distinct
cluster
sampl
form
singl
cluster
cluster
show
signific
downregul
immun
function
gene
cluster
contain
sequenti
sampl
season
flu
case
one
case
though
gene
express
level
similar
surviv
case
surviv
gene
form
four
cluster
b
c
cluster
c
contain
major
analyz
gene
downregul
cluster
dynam
cytokineschemokin
protein
level
patient
shown
figur
data
singl
critic
patient
suffer
season
influenza
also
present
comparison
plasma
cytokin
chemokin
show
distinct
pattern
sequenti
sampl
fatal
surviv
case
patient
exhibit
differ
pattern
compar
other
first
comprehens
studi
address
import
issu
identif
marker
sever
infect
dynam
immun
respons
sever
diseas
evalu
sever
paramet
investig
initi
earli
phase
pandem
isol
mild
infect
design
ward
obligatori
therefor
could
collect
sampl
initi
antivir
therapi
data
truli
repres
acut
phase
mild
diseas
hand
critic
ill
patient
given
oseltamivir
immedi
confirm
infect
sampl
collect
subsequ
underli
medic
condit
present
one
survivor
critic
ill
patient
associ
comorbid
alon
seem
respons
complic
aberr
immun
respons
absenc
viremia
patient
categori
rel
low
viral
load
lung
aspir
critic
ill
patient
suggest
enhanc
replic
viru
may
import
contributor
pathogenesi
figur
viral
load
lung
aspir
independ
fatal
contrast
among
spanish
patient
mild
critic
case
respect
posit
serum
viral
rna
signific
differ
viral
load
studi
use
cdc
primer
real
time
pcr
http
critic
case
bled
alreadi
oseltamivir
treatment
negat
sensit
pcr
effect
antivir
therapi
delay
collect
sampl
respons
differ
result
absenc
uniform
mutat
fatal
casesderiv
indian
isol
suggest
limitedno
role
mutant
viru
pathogenesi
viremia
associ
outcom
infect
fatal
nonfat
case
virem
serum
hiantibodi
posit
note
critic
ill
spanish
patient
critic
ill
patient
india
elisa
could
detect
antibodi
everi
patient
absenc
viremia
among
indian
patient
may
due
earli
antibodi
respons
presenc
antibodi
sever
indian
patient
hi
antibodi
screen
indic
switch
innat
adapt
immun
poor
outcom
despit
switch
may
probabl
attribut
time
shift
role
antibodi
diseas
sever
significantli
higher
titr
antibodi
critic
ill
patient
support
role
pathogenesi
observ
sharp
contrast
sar
patient
examin
canada
document
significantli
lower
antisar
cov
spike
antibodi
titr
critic
ill
patient
though
presenc
neutral
antibodi
protect
influenza
viru
infect
clearanc
infect
mediat
cellular
immun
exclus
presenc
antibodi
patient
categori
document
bia
signific
enhanc
sever
observ
correl
elev
level
cytokin
protein
level
gene
level
identifi
higher
plasma
level
marker
sever
known
marker
influenza
diseas
sever
probabl
involv
tissu
damag
import
mediat
viru
induc
inflamm
recogn
regulatori
antiinflammatori
cytokin
act
multipl
cell
type
regul
immun
inflammatori
respons
known
respons
regul
plasma
level
among
spanish
patient
serum
recogn
hallmark
sever
signific
increas
tlr
level
without
correspond
rise
cytokin
suggest
aberr
immun
respons
critic
ill
patient
possibl
viral
protein
diminish
cytokin
product
rule
similar
invitro
studi
cytokin
storm
associ
pathogenesi
infect
featur
infect
observ
increas
level
plasma
ifng
patient
categori
compar
control
well
basal
gene
express
lung
critic
ill
patient
point
lack
coordin
modul
innat
adapt
immun
respons
pbmc
gene
level
downregul
larg
number
gene
associ
diseas
sever
tabl
figur
profil
indic
massiv
infiltr
monocyterecruit
neutrophil
dcsmacrophag
target
organ
mount
immun
responsetissu
repair
andor
viral
proteininduc
shut
cellular
gene
cell
known
effici
replic
viru
addit
studi
requir
examin
viru
specif
regul
host
antivir
gene
dictat
gener
shut
host
mrna
synthesi
especi
relat
diseas
sever
paradox
constant
inflammatori
signal
provid
signific
increas
sever
chemokin
proinflammatori
cytokin
tnf
lung
cell
may
result
massiv
infiltr
leucocyt
excess
tissu
damag
knowledg
first
report
gene
express
human
lung
cell
differenti
cytokin
level
viral
load
observ
male
pregnant
femal
fatal
case
except
higher
downregul
pregnant
woman
seri
similar
other
intrigu
note
despit
attempt
mount
immun
respons
similar
mildrecov
patient
patient
succumb
diseas
import
recogn
current
studi
examin
virushost
interact
throughout
cours
sever
diseas
limit
studi
absenc
similar
data
mild
case
could
investig
critic
case
suffer
season
influenza
similar
pattern
record
pandem
influenza
case
distinct
differ
record
case
figur
ferret
model
mortal
base
weight
loss
follow
infect
pandem
influenza
viru
sequenti
lung
sampl
document
decreas
gene
express
tnfa
day
anim
show
highest
weight
loss
comparison
human
data
present
studi
tabl
show
lung
critic
ill
patient
sever
chemokinesinflammatori
cytokin
overexpress
thu
gene
express
profil
time
overwhelm
symptom
lung
infect
ferret
decreas
express
match
data
sever
human
case
present
seri
elev
express
final
manuscript
came
across
two
studi
hong
kong
mild
patient
n
non
virem
fatal
case
virem
data
spain
hong
kong
india
suggest
role
host
genet
immun
respons
pandemiccaus
viru
conclus
data
confirm
earlier
find
dysregul
host
respons
sever
infect
influenza
virus
howev
mechan
lead
similar
end
result
seem
vari
type
viral
infect
indepth
studi
understand
role
virusvir
protein
modul
host
respons
need
undertaken
prioriti
identif
specif
pathway
might
provid
clue
includ
immunomodul
treatment
sever
case
albeit
conjunct
potent
antivir
